Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

E. Montes Servin



Author of

  • +

    P1.07 - Immunology and Immunotherapy (ID 693)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Immunology and Immunotherapy
    • Presentations: 1
    • +

      P1.07-040 - Prognosis-Relevant Subgroups in NSCLC According to Granulocytic Myeloid-Derived Suppressor Cell Frequency and Cytokine Levels (ID 9397)

      09:30 - 09:30  |  Author(s): E. Montes Servin

      • Abstract
      • Slides

      Background:
      The percentage of Polymorphonuclear-MDSCs (PMN-MDSCs) has emerged as an independent prognostic factor for survival in Non-small cell lung cancer (NSCLC) patients. Similarly, cytokine profiles have been used to identify subgroups of NSCLC patients with different clinical outcomes. This prospective study investigated whether the percentage of circulating PMN-MDSC, in conjunction with the levels of plasma cytokines, was more informative of disease progression than the analysis of either factor alone.

      Method:
      We analyzed the phenotypic and functional profile of peripheral blood T-cell subsets (CD3[+], CD3[+]CD4[+] and CD3[+]CD8[+]), neutrophils (CD66b[+]) and polymorphonuclear-MDSCs (PMN-MDSCs; CD66b[+]CD11b[+]CD15[+]CD14-) as well as the concentration of 14 plasma cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-17A, IL-27, IL-29, IL-31, and IL-33, TNF-α, IFN-γ) in 90 treatment-naïve NSCLC patients and 25 healthy subjects (HS).

      Result:
      In contrast to HS, NSCLC patients had a higher percentage of PMN-MDSCs and neutrophils (P<0.0001) but a lower percentage of CD3[+], CD3[+]CD4[+] and CD3[+]CD8[+] cells. PMN-MDSCs% negatively correlated with the levels of IL1-β, IL-2, IL-27 and IL-29. Two groups of patients were identified according to the percentage of circulating PMN-MDSCs. Patients with low PMN-MDSCs (≤8 %) had a better OS (22.045 months [95% CI: 4.335-739.735]) than patients with high PMN-MDSCs (9.265 months [95% CI: 0-18.810]). OS was significantly different among groups of patients stratified by both PMN-MDSC% and cytokine levels. Figure 1



      Conclusion:
      Our findings provide evidence suggesting that PMN-MDSC% in conjunction with the levels IL-1β, IL-27, and IL-29 could be a useful strategy to identify groups of patients with potentially unfavorable prognoses.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.